Privi Speciality Chemicals Limited (PRIVISCL.NS) Bundle
Dive into a data-driven look at Privi Speciality Chemicals Ltd where momentum shows in quarterly and annual numbers - Q4 FY25 total income jumped to ₹628.36 crores (up 27.39% from Q3 FY25) and FY25 revenue reached ₹2,121.83 crores (a 19.91% rise year-on-year), while trailing twelve-month revenue hit ₹23.42 billion and Q2 FY26 income climbed 26.3% to ₹678.82 crores; profitability strengthened sharply with FY25 net profit at ₹186.99 crores (up 97.03% YoY) and net margins expanding to 8.8% (13.3% in Q2 FY26), ROE at 22.72% and EPS surging (Q2 FY26 EPS ₹24.04; FY EPS ₹68.31), even as leverage and liquidity paint a mixed picture - debt/equity 0.86, long-term debt rising 15% to ₹5,000 million, current ratio 1.25 but quick ratio only 0.41 and interest coverage 4.75 - valuation and market signals show premium expectations with EV/EBITDA at 23.80, P/E ~44.70 and a 52-week stock gain of 63.24% (market cap ~₹119.26 billion as of Dec 17, 2025), and clear growth levers ahead as capacity targets rise from 48,000 to 54,000 MT and management eyes ₹5,000 crores revenue and ₹1,000 crores EBITDA in 3-4 years - read on to unpack what these figures mean for investors.
Privi Speciality Chemicals Limited (PRIVISCL.NS) - Revenue Analysis
- Total income for Q4 FY25: ₹628.36 crores (up 27.39% from Q3 FY25 ₹493.05 crores).
- Annual revenue FY25: ₹2,121.83 crores (up 19.91% from FY24 ₹1,778.53 crores).
- Trailing twelve months (TTM) total revenue: ₹23.42 billion (24.25% YoY growth).
- Q2 FY26 total income: ₹678.82 crores (up 26.3% YoY).
- Revenue per employee: ₹34.85 million.
- Market capitalization (as of 31 Mar 2025): ₹6,660 crores.
| Period | Metric | Value | YoY / QoQ Change |
|---|---|---|---|
| Q3 FY25 | Total income | ₹493.05 crores | - |
| Q4 FY25 | Total income | ₹628.36 crores | QoQ +27.39% |
| Q2 FY26 | Total income | ₹678.82 crores | YoY +26.3% |
| FY24 | Annual revenue | ₹1,778.53 crores | - |
| FY25 | Annual revenue | ₹2,121.83 crores | YoY +19.91% |
| TTM | Total revenue | ₹23.42 billion (≈ ₹2,342 crores) | YoY +24.25% |
| Employees (derived) | Revenue per employee | ₹34.85 million | - |
| Market | Market capitalization (31 Mar 2025) | ₹6,660 crores | - |
- Quarterly acceleration: Q4 FY25 sequential revenue jump of 27.39% indicates improving demand or realizations versus Q3 FY25.
- Consistent YoY momentum: FY25 and TTM figures show robust double-digit growth (19.91% and 24.25% respectively), validating scale expansion.
- Operational efficiency: Revenue per employee of ₹34.85 million highlights high productivity and capital/light asset intensity typical of specialty chemical businesses.
- Market confidence: Market cap of ₹6,660 crores as of 31-Mar-2025 reflects investor valuation premium relative to trailing revenues.
Privi Speciality Chemicals Limited (PRIVISCL.NS) - Profitability Metrics
Privi Speciality Chemicals reported strong profitability gains across FY25 and into FY26, driven by margin expansion and higher bottom-line growth.
- Q4 FY25 net profit: ₹66.52 crores (up 49.8% QoQ from ₹44.43 crores in Q3 FY25).
- FY25 annual net profit: ₹186.99 crores (up 97.03% from ₹94.90 crores in FY24).
- Net profit margin: 8.8% in FY25 vs 5.4% in FY24.
- Q2 FY26 EPS: ₹24.04 (up 51.7% QoQ).
- Q2 FY26 net profit margin: 13.3% (up from 8.8% in Q2 FY25).
- Return on equity (ROE): 22.72%.
| Period | Net Profit (₹ crores) | Net Profit Margin | EPS (₹) | YoY / QoQ Change |
|---|---|---|---|---|
| Q3 FY25 | 44.43 | - | - | - |
| Q4 FY25 | 66.52 | - | - | +49.8% QoQ vs Q3 FY25 |
| FY24 (Annual) | 94.90 | 5.4% | - | Baseline |
| FY25 (Annual) | 186.99 | 8.8% | - | +97.03% YoY vs FY24 |
| Q2 FY25 | - | 8.8% | - | Baseline for Q2 comparison |
| Q2 FY26 | - | 13.3% | 24.04 | EPS +51.7% QoQ; Margin up vs Q2 FY25 |
| ROE (latest reported) | 22.72% | |||
- Margin trajectory: improvement from 5.4% to 8.8% year-on-year (FY24→FY25) and further uplift in Q2 FY26 to 13.3% versus Q2 FY25.
- Profitability drivers: higher realization, cost efficiencies and scale leading to near-doubling of annual net profit in FY25.
Further investor-focused context and shareholding/activity details can be explored here: Exploring Privi Speciality Chemicals Limited Investor Profile: Who's Buying and Why?
Privi Speciality Chemicals Limited (PRIVISCL.NS) - Debt vs. Equity Structure
Privi Speciality Chemicals shows a financing profile that balances leverage and liquidity. The reported debt-to-equity ratio of 0.86 signals moderate reliance on borrowed funds relative to shareholder equity, while a current ratio of 1.25 and an interest coverage ratio of 4.75 point to adequate short-term liquidity and sufficient operating earnings to meet interest obligations.- Debt-to-equity: 0.86 - moderate leverage
- Interest coverage ratio: 4.75 - earnings cover interest comfortably
- Current ratio: 1.25 - adequate short-term asset coverage
- Long-term debt growth: increased 15% to ₹5,000 million in FY25 (from ₹4,000 million in FY24)
- Current liabilities growth: rose 23.1% to ₹11,000 million in FY25 (from ₹9,000 million in FY24)
- Total assets & liabilities growth: up 19% to ₹28,000 million in FY25 (from ₹23,000 million in FY24)
| Metric | FY24 | FY25 | Change |
|---|---|---|---|
| Long-term debt | ₹4,000 million | ₹5,000 million | +15% |
| Current liabilities | ₹9,000 million | ₹11,000 million | +23.1% |
| Total assets & liabilities | ₹23,000 million | ₹28,000 million | +19% |
| Debt-to-equity ratio | 0.86 | - | |
| Interest coverage ratio | 4.75 | - | |
| Current ratio | 1.25 | - | |
- The 0.86 debt-to-equity ratio suggests room to raise capital via debt if required, without excessive financial risk.
- Rising long-term debt (15% increase) should be monitored for use of proceeds-capex, expansion, or working capital.
- Current liabilities grew faster (23.1%) than overall assets (19%), tightening near-term liquidity despite a current ratio above 1.0.
- An interest coverage of 4.75 indicates operating profits are sufficient to service interest, but not so large as to be comfortably immune to earnings shocks.
Privi Speciality Chemicals Limited (PRIVISCL.NS) - Liquidity and Solvency
Privi Speciality Chemicals shows a mixed liquidity profile with adequate short-term coverage but limited near-cash buffers, alongside moderate leverage and a comfortable interest-servicing capacity.- Current ratio: 1.25 - sufficient short-term assets to cover current liabilities.
- Quick ratio: 0.41 - indicates potential liquidity stress if inventory cannot be converted rapidly to cash.
- Interest coverage ratio: 4.75 - strong ability to meet interest obligations from operating earnings.
- Debt-to-equity ratio: 0.86 - moderate financial leverage, not overly aggressive but notable reliance on debt.
| Metric | Value | Comment |
|---|---|---|
| Current ratio | 1.25 | Short-term coverage adequate |
| Quick ratio | 0.41 | Low cash/receivables relative to liabilities |
| Interest coverage ratio | 4.75 | Comfortable cushion to service interest |
| Debt-to-equity ratio | 0.86 | Moderate leverage |
| Total assets & liabilities (FY24 → FY25) | ₹23 billion → ₹28 billion | 19% growth YoY in scale |
| Total income (Q2 FY25 → Q2 FY26) | ₹537.27 cr → ₹678.82 cr | 26.3% YoY increase |
- Balance-sheet expansion: Total assets and liabilities increased 19% to ₹28 billion in FY25 from ₹23 billion in FY24, reflecting growth-funded expansion.
- Revenue momentum: Total income for Q2 FY26 was ₹678.82 crore, up 26.3% from ₹537.27 crore in Q2 FY25, supporting operating cash generation.
- Working-capital sensitivity: With a quick ratio of 0.41, working-capital management (inventory turns, receivables collection) will be key to avoiding short-term funding pressure.
Privi Speciality Chemicals Limited (PRIVISCL.NS) - Valuation Analysis
Privi Speciality Chemicals trades at a premium relative to many peers, with market-implied expectations of continued top-line and margin expansion. Key headline metrics highlight investor willingness to pay for growth and profitability.- Enterprise Value / EBITDA (EV/EBITDA): 23.80 - indicates a premium valuation versus typical chemical sector ranges.
- Price / Sales (P/S): 5.36 - markets are pricing in significant future revenue growth and margin sustainability.
- Price / Earnings (P/E): 44.70 based on EPS of ₹68.31 - suggests high earnings multiple driven by strong recent performance and growth assumptions.
- Return on Equity (ROE): 22.72% - demonstrates effective use of shareholders' equity to generate returns.
- Market Capitalization (as of 17 Dec 2025): ₹119.26 billion - a large-cap stature supporting liquidity and institutional interest.
- 52-week stock price change: +63.24% - strong investor confidence and momentum over the past year.
| Metric | Value | Implication |
|---|---|---|
| EV/EBITDA | 23.80 | Premium - implies expectations of sustained EBITDA growth or higher margins |
| P/S | 5.36 | High revenue multiple - market pricing in above-sector revenue trajectory |
| Market Cap (17‑Dec‑2025) | ₹119.26 billion | Large-cap; supports institutional ownership and liquidity |
| 52‑Week Change | +63.24% | Strong price momentum and investor appetite |
| EPS | ₹68.31 | Robust per-share profitability |
| P/E | 44.70 | High earnings multiple - growth premium priced in |
| ROE | 22.72% | Efficient capital deployment and attractive shareholder returns |
- Valuation drivers to watch: EBITDA margin trajectory, revenue growth sustainability, capex and working capital trends, and commodity/FX exposure that could compress or expand multiples.
- Relative positioning: Given EV/EBITDA ~23.8 and P/E ~44.7, Privi sits well above cyclical chemical peers - price action (52-week +63.24%) reflects that premium narrative.
Privi Speciality Chemicals Limited (PRIVISCL.NS) - Risk Factors
Key balance-sheet and operational metrics point to areas investors should monitor closely. Below are principal risks derived from recent financial data and trends.
- Leverage risk: Debt-to-equity ratio of 0.86 signals moderate financial leverage that can amplify earnings volatility and constrain flexibility during downturns.
- Liquidity risk: Quick ratio of 0.41 indicates limited near-term liquid resources; reliance on inventory turnover or receivable collections is high.
- Interest burden sensitivity: Although the interest coverage ratio is a healthy 4.75, any material drop in EBITDA could weaken the company's ability to service debt.
- Rising liabilities: Total liabilities increased 19% to ₹28,000 million (₹28 billion) in FY25, which may limit room for additional borrowing or capital investments.
- Revenue concentration & cyclicality: Despite a strong top-line growth in Q2 FY26, cyclicality in specialty chemicals end-markets could reverse sales momentum.
- Market valuation exposure: Market capitalization of ₹119.26 billion (as of 17 Dec 2025) exposes the company to sentiment-driven share-price swings if operational metrics deteriorate.
| Metric | Value | Period/Notes |
|---|---|---|
| Debt-to-Equity Ratio | 0.86 | Latest reported |
| Quick Ratio | 0.41 | Latest reported |
| Interest Coverage Ratio | 4.75 | EBITDA / Interest expense |
| Total Liabilities | ₹28,000 million | FY25 (↑19% year-on-year) |
| Total Income (Q2) | ₹678.82 crore | Q2 FY26 (↑26.3% vs ₹537.27 crore in Q2 FY25) |
| Market Capitalization | ₹119.26 billion | As of 17 Dec 2025 |
Areas for ongoing monitoring:
- Working capital management - collections, inventory days, and payable terms given the low quick ratio.
- Debt servicing - maintaining EBITDA margins sufficient to preserve an interest coverage buffer above current levels.
- Liability growth trajectory - whether FY25's 19% rise in total liabilities is a one-off or a continuing trend.
- Revenue sustainability - whether Q2 FY26's 26.3% year-on-year growth converts into consistent full-year performance.
- Market sentiment - impact of operational misses on market cap volatility.
Contextual company profile and strategic background: Privi Speciality Chemicals Limited: History, Ownership, Mission, How It Works & Makes Money
Privi Speciality Chemicals Limited (PRIVISCL.NS) - Growth Opportunities
Privi Speciality Chemicals Limited (PRIVISCL.NS) is pursuing capacity expansion, margin improvement and revenue scaling targets that together shape a clear growth roadmap for investors.- Capacity expansion: production capacity to increase from 48,000 to 54,000 metric tonnes by January 2026 (12.5% uplift).
- Revenue & profitability targets: company aims for ₹5,000 crores in revenue and ₹1,000 crores in EBITDA over the next 3-4 years.
- Recent top-line momentum: total income for Q2 FY26 was ₹678.82 crores, up 26.3% from ₹537.27 crores in Q2 FY25.
| Metric | Value / Date |
|---|---|
| Planned production capacity | 54,000 MT by Jan 2026 (from 48,000 MT) |
| Target revenue | ₹5,000 crores (3-4 years) |
| Target EBITDA | ₹1,000 crores (3-4 years) |
| Q2 FY26 total income | ₹678.82 crores (↑26.3% vs Q2 FY25: ₹537.27 cr) |
| Market capitalization | ₹119.26 billion (as of 17 Dec 2025) |
| Return on Equity (ROE) | 22.72% |
| Total assets & liabilities | ₹28 billion in FY25 (↑19% from ₹23 billion in FY24) |
- Strategic implications: capacity increase supports higher volumes to meet domestic and export demand; EBITDA target implies sustained margin expansion or scale benefits.
- Balance-sheet signal: 19% growth in total assets and liabilities to ₹28 billion in FY25 reflects ongoing investment and financing to support scaling.
- Profitability metric: ROE of 22.72% indicates effective use of shareholder equity to generate returns.
Privi Speciality Chemicals Limited (PRIVISCL.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.